This is a proposal to renew a T32 grant to support training for eight physicians committed to a career in cancer research. The goal of this program is to train the next generation of physician scientists in medical, surgical, and radiation oncolog in both fundamental and advanced methods of cancer research, strengthening the ties between the laboratory and clinic. The program is multi-specialty and multidisciplinary in its orientation and governance, and includes laboratories and mentors that represent all of the clinical subspecialties of cancer and a broad array of research interests. The program emphasizes the importance of translating new findings in the fields of cancer biology, genetics, experimental therapeutics, immunology, molecular imaging, outcomes and epidemiology into useful clinical application. The pool of candidates is derived primarily from the Massachusetts General Hospital (MGH) clinical residency and fellowship programs in medical oncology, radiation oncology, and surgery. The quality of these candidates is outstanding. The mentors are similarly outstanding, and have outstanding records of mentoring, research, funding and collaboration. The mentors are based mainly at the MGH Cancer Center, but are also from Massachusetts Institute of Technology and member institutions of the Dana-Farber/Harvard Cancer Center (DF/HCC). Mentors interact extensively through their research collaborations and participation in the cancer center. This training program and the cancer center are built on the cornerstone of integrating laboratory, clinical, and population science research through disease-based programs which have been established for each type of cancer. The program provides both project-oriented research experience and complementary didactic education for trainees. A high priority is placed on careful monitoring of trainees'progress by the program Director and Co-director, the Executive Committee, and individual mentors, including regular written reports from the trainees and mentors. The track record of former program trainees serves as a strong endorsement of the quality of this program. The program actively recruits women and minority candidates, and new mechanisms have been implemented to enhance these efforts.

Public Health Relevance

The goal of this program is to train the next generation of physician scientists in medical, surgical , and radiation oncology in both fundamental and advanced methods of cancer research, strengthening the ties between the laboratory and clinic. The program is multi-specialty and multidisciplinary in its orientation and governance, and includes laboratories and mentors that represent all of the clinical subspecialties of cancer and a broad array of research interests. The program emphasizes the importance of translating new findings in the fields of cancer biology, genetics, experimental therapeutics, immunology, molecular imaging, outcomes and epidemiology into useful clinical application.

Agency
National Institute of Health (NIH)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA071345-18
Application #
8728751
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Brunner, Andrew M; Hobbs, Gabriela; Jalbut, Marla M et al. (2016) A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma 57:1197-200
Brunner, Andrew M; Steensma, David P (2016) Myelodysplastic syndrome associated with acquired beta thalassemia: "BTMDS". Am J Hematol 91:E325-7
Nipp, Ryan D; Greer, Joseph A; El-Jawahri, Areej et al. (2016) Age and Gender Moderate the Impact of Early Palliative Care in Metastatic Non-Small Cell Lung Cancer. Oncologist 21:119-26
Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504
DePeralta, Danielle K; Wei, Lan; Ghoshal, Sarani et al. (2016) Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer 122:1216-27
Elkabets, Moshe; Pazarentzos, Evangelos; Juric, Dejan et al. (2015) AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 27:533-46
Miao, Benchun; Ji, Zhenyu; Tan, Li et al. (2015) EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov 5:274-87
Platt, Mia Y; Fathi, Amir T; Borger, Darrell R et al. (2015) Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn 17:661-8
Juric, Dejan; Castel, Pau; Griffith, Malachi et al. (2015) Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518:240-4
Alagesan, Brinda; Contino, Gianmarco; Guimaraes, Alexander R et al. (2015) Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res 21:396-404

Showing the most recent 10 out of 55 publications